Discovery of new biomarker could provide personalized treatment options for bladder cancer
Share

A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report in a recent study. Bladder cancers are categorized into subtypes based on molecular features. These subtypes are associated with different prognoses and responses to conventional treatments such as chemotherapy. A type of bladder cancer called p53-like bladder cancer, named after an active gene signature its associated with, is typically associated with a particularly aggressive course though prognosis among individuals can be quite variable. The research team at Mount Sinai has identified two microRNA activity-based biomarkers that can provide insights regarding which patients with p53-like bladder cancer may have a better versus worse prognosis. MicroRNA is a type of genetic material that regulates gene expression.

The study, published in July 2018 in Oncogene, describes how researchers applied a computational method they had previously developed, called ActMiR, to bladder cancer genomic data in The Cancer Genomic Atlas (TCGA) to identify two novel biomarkers in p53-like bladder cancers that could accurately predict patient outcomes. The biomarker models were validated in multiple independent data sets.

“Our method for quantifying microRNA activity has been validated in multiple subtypes of breast cancer. I am glad

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD